+5,979.9%
MCD vs GSK
+1,705.8%
+4,274.1%
-73.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.5% | -1.9% | +0.4% | -1.0% |
| 7D | -2.8% | -1.8% | -1.0% | -2.4% |
| 30D | -6.0% | -2.2% | -3.8% | -5.5% |
| 3M | -5.6% | -1.8% | -3.8% | -5.2% |
| 6M | -21.9% | -10.6% | -11.2% | -19.7% |
| YTD | -14.7% | +4.4% | -19.1% | -16.1% |
| 1Y | -17.3% | +30.4% | -47.7% | -23.5% |
| 3Y | -2.2% | +60.1% | -62.2% | -15.6% |
| 5Y | +20.3% | +46.8% | -26.5% | +5.1% |
| 10Y | +180.7% | +79.2% | +101.5% | +130.8% |
| All | +5,979.9% | +1,705.8% | +4,274.1% | +2,444.8% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling